Drug safety. FDA panel urges caution on many anti-inflammatory drugs

Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a.
No abstract available

Publication types

  • News

MeSH terms

  • Advisory Committees*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology
  • Celecoxib
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Drug Labeling*
  • Drug and Narcotic Control
  • Humans
  • Isoxazoles / adverse effects
  • Isoxazoles / therapeutic use
  • Lactones / adverse effects
  • Lactones / therapeutic use
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Stroke / chemically induced
  • Stroke / epidemiology
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Sulfones / adverse effects
  • Sulfones / therapeutic use
  • United States
  • United States Food and Drug Administration*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Isoxazoles
  • Lactones
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • valdecoxib
  • Celecoxib